04/27/2026
Eli Lilly and Company has entered a definitive agreement to acquire Ajax Therapeutics Inc., a biopharmaceutical company developing next generation JAK inhibitors for patients with myeloproliferative neoplasms (MPNs). ➡️ https://hubs.li/Q04dyHH30